Literature DB >> 8994150

Can preference scores for discrete states be used to derive preference scores for an entire path of events? An application to prenatal diagnosis.

M Kuppermann1, S Shiboski, D Feeny, E P Elkin, A E Washington.   

Abstract

The authors conducted a study exploring whether preferences for sequences of events can be approximated by preferences for component discrete states. Visual-analog-scale (VAS) and standard-gamble (SG) scores for a subset of the possible sequences of events (path states) and component temporary and chronic outcomes (discrete states) that can follow prenatal diagnostic decisions were elicited from 121 pregnant women facing a choice between chorionic villus sampling and amniocentesis. For individuals, preference scores for path states could not be predicted easily from discrete-state scores. Mean path-state VAS scores, however, were predicted reasonably accurately by multiple regression models (R2 = 0.85 and 0.82 for two different anchoring schemes), with most measured scores lying within the 95% confidence intervals of the derived scores. It is concluded that, for individual patient decision making, preferences for path states should be elicited. When mean preference values for a population are sought, however, it may be reasonable to derive regression weights from a subset of respondents and then to apply those weights to preferences for discrete states elicited from a larger group.

Entities:  

Mesh:

Year:  1997        PMID: 8994150     DOI: 10.1177/0272989X9701700105

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  10 in total

Review 1.  Valuing health-related quality of life. A review of health state valuation techniques.

Authors:  C Green; J Brazier; M Deverill
Journal:  Pharmacoeconomics       Date:  2000-02       Impact factor: 4.981

Review 2.  Valuing health-related quality of life. Issues and controversies.

Authors:  P Dolan
Journal:  Pharmacoeconomics       Date:  1999-02       Impact factor: 4.981

3.  Measurement of short term health effects in economic evaluations.

Authors:  A M Holmes
Journal:  Pharmacoeconomics       Date:  1998-02       Impact factor: 4.981

4.  Holistic preferences for 1-year health profiles describing fluctuations in health: the case of chronic obstructive pulmonary disease.

Authors:  Maureen P M H Rutten-van Mölken; Martine Hoogendoorn; Leida M Lamers
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

5.  Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C.

Authors:  U Siebert; G Sroczynski; S Rossol; J Wasem; U Ravens-Sieberer; B M Kurth; M P Manns; J G McHutchison; J B Wong
Journal:  Gut       Date:  2003-03       Impact factor: 23.059

6.  Clinical effectiveness and cost effectiveness of tailoring chronic hepatitis C treatment with peginterferon alpha-2b plus ribavirin to HCV genotype and early viral response: a decision analysis based on German guidelines.

Authors:  Uwe Siebert; Gaby Sroczynski; Pamela Aidelsburger; Siegbert Rossol; Jürgen Wasem; Michael P Manns; John G McHutchison; John B Wong
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

Review 7.  Who should be offered prenatal diagnosis? The 35-year-old question.

Authors:  M Kuppermann; J D Goldberg; R F Nease; A E Washington
Journal:  Am J Public Health       Date:  1999-02       Impact factor: 9.308

8.  Health State Utilities for Adverse Events Associated with Chimeric Antigen Receptor T-Cell Therapy in Large B-Cell Lymphoma.

Authors:  Timothy A Howell; Louis S Matza; Monika P Jun; Jacob Garcia; Annette Powers; David G Maloney
Journal:  Pharmacoecon Open       Date:  2022-02-07

9.  Acute and chronic impact of cardiovascular events on health state utilities.

Authors:  Louis S Matza; Katie D Stewart; Shravanthi R Gandra; Philip R Delio; Brett E Fenster; Evan W Davies; Jessica B Jordan; Mickael Lothgren; David H Feeny
Journal:  BMC Health Serv Res       Date:  2015-04-22       Impact factor: 2.655

10.  Health state utilities associated with treatment for transfusion-dependent β-thalassemia.

Authors:  Louis S Matza; L Clark Paramore; Katie D Stewart; Hayley Karn; Minesh Jobanputra; Andrew C Dietz
Journal:  Eur J Health Econ       Date:  2019-12-11
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.